Total reported value
$652.4M
Reporting period: 2026-03-31 · Number of holdings: 16
JOHNSON & JOHNSON disclosed 16 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $652.4M and a quarterly turnover rate of 20.2%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "J"
Add NBTX
0.0% $43.6M
Trim RAPP
0.0% $1.7M
Add PTGX
0.0% $44.2M
Trim LEGN
0.0% -$3.0M
Add CVRX
0.0% $9.5M
Trim MGTX
0.0% $4.7M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PTGX | Protagonist Therapeutics INC | Stock-Other | 39.57% | +1.03% | — | |
| 2 | NBTX | Nanobiotix SA - Adr | Stock-Other | 26.61% | +3.18% | — | |
| 3 | MGTX | MeiraGTx Holdings plc | Stock-Other | 8.82% | -0.69% | — | |
| 4 | RAPP | Rapport Therapeutics INC | Stock-Other | 8.56% | -1.19% | — | |
| 5 | CVRX | Cvrx INC | Stock-Other | 5.84% | +0.69% | — | |
| 6 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 3.96% | -0.12% | — | |
| 7 | LEGN | Legend Biotech Corp-adr | Stock-Other | 2.26% | -0.93% | — | |
| 8 | XNCR | Xencor INC | Stock-Other | 1.38% | -0.68% | — | |
| 9 | PRCT | Procept Biorobotics CORP | Stock-Other | 1.37% | -0.66% | — | |
| 10 | FATE | Fate Therapeutics INC | Stock-Other | 0.62% | +0.02% | — | |
| 11 | NMRA | Neumora Therapeutics INC | Stock-Other | 0.55% | -0.05% | — | |
| 12 | RLYB | Rallybio CORP | Stock-Other | 0.21% | +0.21% | NEW | |
| 13 | VOR | Vor Biopharma INC | Stock-Other | 0.15% | +0.02% | — | |
| 14 | LAB | Standard Biotools INC | Stock-Other | 0.04% | -0.03% | — | |
| 15 | NNOX | Nano-X Imaging Ltd. | Stock-Other | 0.03% | -0.05% | -47.40% | |
| 16 | ACET | Adicet Bio INC | Stock-Other | 0.02% | -0.01% | — |
Performance for Q3 2026
+24.7%
Performance Last 4 Quarters
+116.9%
Based on 85% of reported portfolio value with available pricing
Not enough sector-mapped data yet
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 16 | $652.4M | 20 | |
| 2025-12-31 | 17 | $555.0M | 21 | |
| 2025-09-30 | 20 | $503.9M | 52 | |
| 2025-06-30 | 20 | $334.1M | 0 | |
| 2025-03-31 | 20 | $341.9M | 0 | |
| 2024-12-31 | 20 | $386.1M | 0 | |
| 2024-09-30 | 20 | $427.3M | 0 | |
| 2024-06-30 | 20 | $400.7M | 0 | |
| 2024-03-31 | 22 | $4.4B | 0 | |
| 2023-12-31 | 23 | $4.4B | 0 | |
| 2023-09-30 | 24 | $271.5M | 0 | |
| 2023-06-30 | 22 | $322.1M | 0 | |
| 2023-03-31 | 23 | $307.4M | 0 | |
| 2022-12-31 | 22 | $343.7M | 0 | |
| 2022-09-30 | 22 | $339.8M | 0 | |
| 2022-06-30 | 22 | $391.5M | 0 | |
| 2022-03-31 | 22 | $529.0M | 0 | |
| 2021-12-31 | 24 | $878.4M | 0 | |
| 2021-09-30 | 25 | $1.1B | 0 |
Johnson & Johnson's most significant position changes for 2026-03-31: Sold out: Rallybio CORP; Sold out: Lyell Immunopharma INC (LYEL); New buy: Rallybio CORP (RLYB); Trim: Nano-X Imaging Ltd. (NNOX) — shares -47.40%.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NBTX | Nanobiotix SA - Adr | +3.2% | — | Unchanged |
| 2 | PTGX | Protagonist Therapeutics INC | +1% | — | Unchanged |
| 3 | CVRX | Cvrx INC | +0.7% | — | Unchanged |
| 4 | FATE | Fate Therapeutics INC | 0% | — | Unchanged |
| 5 | VOR | Vor Biopharma INC | 0% | — | Unchanged |
| 6 | ACET | Adicet Bio INC | 0% | — | Unchanged |
| 7 | LAB | Standard Biotools INC | 0% | — | Unchanged |
| 8 | NMRA | Neumora Therapeutics INC | -0.1% | — | Unchanged |
| 9 | NNOX | Nano-X Imaging Ltd. | -0.1% | -47.40% | Trim |
| 10 | CTNM | Contineum Therapeutics Inc-a | -0.1% | — | Unchanged |
| 11 | PRCT | Procept Biorobotics CORP | -0.7% | — | Unchanged |
| 12 | XNCR | Xencor INC | -0.7% | — | Unchanged |
| 13 | MGTX | MeiraGTx Holdings plc | -0.7% | — | Unchanged |
| 14 | LEGN | Legend Biotech Corp-adr | -0.9% | — | Unchanged |
| 15 | RAPP | Rapport Therapeutics INC | -1.2% | — | Unchanged |
| 16 | ✓ | Rallybio CORP | — | EXIT | Sold out |
| 17 | LYEL | Lyell Immunopharma INC | — | EXIT | Sold out |
| 18 | RLYB | Rallybio CORP | — | NEW | New buy |
Institutions with a similar AUM
CIK 0001577552
Total reported value
$652.6M
2 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001538383
Total reported value
$652.7M
1,945 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0000902528
Total reported value
$651.9M
117 stks
2026-03-31
AUM within 0.1% of this institution
Institutions with overlapping top holdings
CIK 0000924020
Total reported value
$978.2M
21 stks
2021-06-30
Stale — no recent filing
2 of the top 5 holdings overlap, including Protagonist Therapeutics INC
CIK 0001121404
Total reported value
$336.0M
9 stks
2026-03-31
1 of the top 5 holdings overlap, including MeiraGTx Holdings plc
CIK 0001274403
Total reported value
$677.1M
10 stks
2026-03-31
1 of the top 5 holdings overlap, including Rapport Therapeutics INC